Abstract 5737
Background
HER2 breast cancer status determines patients’ eligibility for targeted therapy. HER2 level of amplification is associated with a better response to anti-HER2 therapy. Benefit of anti-HER2 therapy for equivocal cases remains debated.
Methods
We aimed to better characterize HER2-equivocal breast cancers by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) according to 2018 ASCO/CAP guidelines using PAM50 gene expression-based molecular subtyping and to investigate genome-wide copy number alterations of these cases. PAM50 (nCounter assay; Nanostring) was performed on RNA from FFPE samples of 60 HER2-equivocal cases. These cases were subsequently analyzed by Agilent 60-mer oligonucleotide microarrays for array-based comparative genomic hybridization (aCGH).
Results
The 60 HER2-equivocal cases were classified as Luminal B in 31 cases (52%), HER2-Enriched in 14 cases (23%), Luminal A in 13 cases (22%) and Basal-like in 2 cases (3%) using PAM50. By IHC, 52 cases (87%) were ER+, 43 (72%) were also PgR+, 40 (67%) were grade III and 45 (75%) showed a high Ki67 > 20%. With aCGH, 23 cases (38%) presented chr 17q large copy number gain, 14 (23%) showed segmental copy number gain including HER2, 10 (17%) showed HER2 amplification, one (2%) showed a large copy number loss and 12 cases (20%) didn’t show any copy number alteration of the chr 17. Out of the 14 PAM50 HER2-Enriched cases, only 5 showed HER2 genomic amplification (Table). In total, 14 cases (23%) were discordant between molecular classification and genomic alteration status of the chr 17.Table:
260P
Genomic alterations of chromosome 17 | Basal- like | HER2- Enriched | Luminal A | Luminal B | Total |
---|---|---|---|---|---|
HER2 amplified | 0 | 5 | 2 | 3 | 10 |
Large copy number gain | 0 | 1 | 5 | 17 | 23 |
Segmental copy number gain | 2 | 5 | 4 | 3 | 14 |
No alteration | 0 | 3 | 2 | 7 | 12 |
Large copy number loss | 0 | 0 | 0 | 1 | 1 |
Total | 2 | 14 | 13 | 31 | 60 |
Conclusions
Using PAM50, the majority of HER2-equivocal cases were classified as Luminal tumors (Luminal B 52% and A 22%) and harbored mostly at the genomic level chr 17 segmental or large copy number gains. As there is no evidence of benefit of anti-HER2 therapy in these cases, it emphasizes the need of genomic status determination of HER2-equivocal cases.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Anne Vincent-Salomon.
Funding
Has not received any funding.
Disclosure
P. Morel: Full / Part-time employment: Nanostring. H.A. Brauer: Full / Part-time employment: Nanosting. A. Vincent-Salomon: Advisory / Consultancy, Consulting fees: Roche; Advisory / Consultancy, Consulting fees: AstraZeneca; Non-remunerated activity/ies, Contracted Research: Nanostring. All other authors have declared no conflicts of interest.
Resources from the same session
5887 - Factors of importance in procuring tumoroids from colorectal liver metastasis biopsies for precision medicine.
Presenter: Lars Henrik Jensen
Session: Poster Display session 2
Resources:
Abstract
2196 - FUSAFE individual patient data meta-analysis (MA) to assess the performance of dihydropyrimidine dehydrogenase (DPD) gene polymorphisms for predicting grade 4-5 fluoropyrimidine (FP) toxicity
Presenter: Marie-Christine Etienne-Grimaldi
Session: Poster Display session 2
Resources:
Abstract
2859 - Treatments (tx) after progression to first-line FOLFOXIRI + bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts): A pooled analysis of TRIBE and TRIBE-2 studies by GONO.
Presenter: Daniele Rossini
Session: Poster Display session 2
Resources:
Abstract
3888 - Randomized phase III study of sequential treatment with capecitabine or 5-fluorouracil (FP) plus bevacizumab (BEV) followed by the addition with oxaliplatin (OX) versus initial combination with OX+FP+ BEV in the first-line chemotherapy for metastatic colorectal cancer: The C-cubed study
Presenter: Takeshi Nagasaka
Session: Poster Display session 2
Resources:
Abstract
1065 - Early tumour shrinkage (ETS), depth of response (DpR) and associated survival outcomes in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC) classified according to Köhne prognostic category: retrospective analysis of the panitumumab (Pmab) PRIME study
Presenter: Andrea Sartore-Bianchi
Session: Poster Display session 2
Resources:
Abstract
1702 - Randomized phase II trial of CAPOX with planned oxaliplatin stop-and-go strategy as adjuvant chemotherapy after curative resection of colon cancer (CCOG-1302 study)
Presenter: Hiroyuki Yokoyama
Session: Poster Display session 2
Resources:
Abstract
5104 - A metabolomic recurrence score for risk-stratification of elderly patients (pts) with early colorectal cancer (eCRC)
Presenter: Samantha Di Donato
Session: Poster Display session 2
Resources:
Abstract
5285 - RAS mutant allele fraction in plasma predicts benefit to anti-angiogenic based first line treatment in metastatic colorectal cancer
Presenter: Giulia Martini
Session: Poster Display session 2
Resources:
Abstract
1790 - Impact of prophylactic systemic antibiotics (SA) on outcome of patients (pts) with RAS-wildtype (RAS-wt) metastatic colorectal carcinoma (mCRC) treated with cetuximab-based first-line therapy. Subgroup analysis of the german non-interventional study ERBITAG
Presenter: Stephan Sahm
Session: Poster Display session 2
Resources:
Abstract
3059 - Intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection (IOCCRC): A randomized, multicenter, prospective, phase III trial
Presenter: Rongxin Zhang
Session: Poster Display session 2
Resources:
Abstract